William Plunkett
University of California, San Francisco
12 Papers
69 Citations
William Plunkett is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Clofarabine & Acute leukemia. The author has an hindex of 4, co-authored 12 publications.
Chat about Author
Papers
Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma
Margaret A. Tempero,William Plunkett,Veronique Ruiz van Haperen,John Hainsworth,Howard S. Hochster,Renato Lenzi,James L. Abbruzzese +6 more
TL;DR: Pharmacokinetic and clinical data in this trial supports the continued evaluation of the FDR infusion strategy with gemcitabine and demonstrates a two-fold increase in intracellular gem citabine triphosphate concentration in the FDR arm.
553
•Journal Article
Difluorodeoxyguanosine: Cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells
Varsha Gandhi,Shin Mineishi,Peng Huang,Yandan Yang,Sherri Chubb,Amy J. Chapman,Billie Nowak,L. W. Hertel,William Plunkett +8 more
TL;DR: Observations indicated that dGuo kinase, which phosphorylates arabinosylguanine, also appears to play a major role in activating dFdG, which is a promising new antimetabolite.
35
Randomized P hase I I C omparison o f D ose-Intense Gemcitabine: T hirty-Minute I nfusion a nd F ixed D ose R ate Infusion i n P atients W ith P ancreatic A denocarcinoma
Margaret A. Tempero,William Plunkett,Veronique Ruiz van Haperen,John Hainsworth,Howard S. Hochster,Renato Lenzi,James L. Abbruzzese +6 more
- 01 Jan 2003
TL;DR: Patients with locally advanced and metastatic pancreatic adenocarcinoma treated with a standard 30-minute or fixed dose rate infusion of gemcitabine experienced consistently more hematologic toxicity, and pharmacokinetic analyses demonstrated a two-fold increase in intracellular gem citabine triphosphate concentration in the FDR arm.
27
Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes
William Plunkett,G. Garcia-Manero,Stephan Faderl,J. E. Cortes,P. A. Boone,C. Hilbe,Simon Green,Judy H. Chiao,Hagop M. Kantarjian +8 more
TL;DR: The primary objective was to define the MTD of the above dosing schedule and the secondary objectives were to characterize the PK/PD effects of sapacitabine and its major metabolite CNDAC.
5
Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).
Apostolia-Maria Tsimberidou,William G. Wierda,Xavier C. Badoux,Sijin Wen,William Plunkett,S. M. O'Brien,Thomas J. Kipps,Jade Jones,Hagop M. Kantarjian,Michael J. Keating +9 more
TL;DR: The design of OFAR2 consisted of oxaliplatin 30 mg/m2 D1-4; oxali platin 30mg/m3 D2 D2; and of course, the drug was titrated according to Boehringer Ingelheim’s “callousness-likelihood” test.
2